12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NuThrax: Phase II started

Emergent began a double-blind, active-controlled, U.S. Phase II trial to evaluate 2 dose levels of NuThrax using 2 and 3-dose immunization schedules in about 168 healthy volunteers. The vaccine has Fast Track designation in the U.S. to prevent anthrax infection and is being developed...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >